BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

Why Cell Therapy Systems Are Going Automatic: A New Era of Manufacturing

Cell therapy stands at the forefront of modern medicine, offering transformative potential for treating a wide spectrum of diseas...

April 22, 2025 | Report

XellSmart Receives IND Approval from FDA for iPSC-Derived Cell Therapy in Parkinson’s Disease

In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submi...

April 16, 2025 | News

Telix Reports Positive Preliminary Results from IPAX-Linz Study of TLX101 in Recurrent High-Grade Glioma

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101&nb...

April 16, 2025 | News

Patent Wars and Patient Lives: Inside Roche vs Natco Over Risdiplam

In a courtroom packed with legal heavyweights, global pharmaceutical giant F. Hoffmann-La Roche AG faced off against Indian generic manufac...

April 14, 2025 | Analysis

RemeGen’s Telitacicept Shows Best-in-Class Efficacy in Phase 3 Trial for Generalized Myasthenia Gravis

On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept...

April 09, 2025 | News

NUS Researchers Harness AI and 3D Bioprinting to Personalise Gum Tissue Grafts

AI-enabled workflow streamlines oral soft tissue fabrication, paving the way for personalised, less invasive dental treatments A team of researchers from ...

April 07, 2025 | News

Senhwa’s CX-4945 Shows Promising Disease Control and Durability in Refractory Basal Cell Carcinoma

Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Res...

April 03, 2025 | News

Ascletis’ ASC30 SQ Injection Shows 36-Day Half-Life in Phase Ib Obesity Trial

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supp...

April 01, 2025 | News

Vaximm Reports Promising Final Data from Phase 2a Trial of Oral Vaccine VXM01 with Avelumab in Recurrent Glioblastoma

Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, announced fina...

March 27, 2025 | News

China’s Innovent Doses First Patient in Phase 3 Trial of HER2-Targeted ADC for Ovarian Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

March 25, 2025 | Report

Akeso Showcases Positive Phase III Safety Run-In Data for Cadonilimab at SGO 2025 in Locally Advanced Cervical Cancer

Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society ...

March 24, 2025 | Report

Dizal to Present New Findings on Golidocitinib-PD-1 Combo and Sunvozertinib-Anlotinib Therapy at ELCC 2025

Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced ...

March 21, 2025 | News

Zhejiang Doer Biologics Completes Phase 2 Enrollment for First-in-Class Tri-Agonist DR10624 in Severe Hypertriglyceridemia

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...

March 11, 2025 | News

Gan & Lee Initiates Phase 2 Trial of Bofanglutide, the First GLP-1 Mono-Agonist to Challenge Tirzepatide in Weight Management

Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a P...

March 11, 2025 | News

Stay Connected